Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-27 12:57:43 - browse：3363

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： The tragedy of Johnson & Johnson’s Covid vaccine

entertainment

WSS

Copay coupons to count toward deductibles, after Biden court move

FDA clears AI tool for detecting skin cancer

A controversial new treatment promises to make little people taller

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Medicare Advantage today, explained in one chart

NIH director takes cautious approach to Biden drug pricing priority

knowledge

Wikipedia

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

The a glaring gap in research on serious mental illness and primary care

Alkermes shareholders re

When waiting feels immoral: Empathy in the emergency department

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA clears AI tool for detecting skin cancer

Apple is now the first public company to be valued at $3 trillion

eGenesis tests gene

DIEP, the 'gold standard' of breast reconstruction, is under threat

Humana cuts profit projections as Medicare Advantage costs soar

focus

Physicians aren't 'burning out.' They're suffering from moral injury

How digital therapeutics firms are pivoting after Pear's bankruptcy

FDA scientists endorse Pfizer/BioNTech Covid

FDA clears AI tool for detecting skin cancer

Chris Christie meets with Zelenskyy during Ukraine trip

Elizabeth Holmes banned from government health programs

leisure time

entertainment

entertainment

focus